SecBot SecBot

Kidney PATIENT Act of 2023

H.R. 5074 Rep. Earl Carter (R-GA-1) In committee
Bill text PDF
  1. Introduced Jul 28
  2. Committee Jul 28
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jul 28, 2023Next: House vote
869d ago Jun 11, 2024: Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-548, Part I.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
4companies, 13 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

4 companies
Companies by sector
Biotech & Pharma 3Medical Devices & Healthcare 1
Search all 4 companies, their asks and price moves Subscribe

Summary

Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 or the Kidney PATIENT Act of 2023

Full summary2 paragraphs

This bill delays a change to the payment methodology under Medicare for oral drugs that are used to treat end-stage renal disease (ESRD).

Under current regulations, beginning January 1, 2025, the Centers for Medicare & Medicaid Services will incorporate payments for oral-only ESRD drugs into the ESRD prospective payment system rather than issuing separate payments to ESRD facilities. The bill delays implementation of this policy until January 1, 2033, or until an approved intravenous drug is available, whichever is earlier.

Library of Congress summary, Jul 28, 2023

Summary versions
  • Introduced in HouseJul 28, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.